GlassScriptPhysician profile
Rudyard L Dimson
NPI 1700956356
$3,024.65
in general payments reported to CMS, 2019-2025
22 companies · $571 in 2025
The $571 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $308 · 2021: $279 · 2022: $488 · 2023: $582 · 2024: $655 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,808.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $576.25 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $457.59 | 2020-2025 | Jardiance, Stiolto Respimat, Tradjenta |
| Lilly USA, LLC | $427.21 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $360.78 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Exact Sciences Corporation | $261.70 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $222.28 | 2019-2025 | |
| Glaxosmithkline, LLC. | $137.19 | 2020-2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.71 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $84.53 | 2021-2025 | Breztri |
| Novartis Pharmaceuticals Corporation | $49.70 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $44.02 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.59 | 2024-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $40.51 | 2022-2023 | |
| Amarin Pharma, INC. | $37.78 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $35.53 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $32.88 | 2022-2023 | Eliquis |
| Merck Sharp & Dohme LLC | $31.68 | 2020-2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Abbvie INC. | $28.64 | 2025 | |
| Abbott Laboratories | $22.61 | 2024 | Freestyle Libre 3 |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.61 | 2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $14.16 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rudyard Dimson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.